Phuturdex › Diseases › Pheochromocytoma
Drugs in development · updated 30 October 2026
Pheochromocytoma: drugs in development
As of 30 October 2026 there are 25 active clinical trials (recruiting or ongoing, phases I–III) on 29 drugs for pheochromocytoma. 14 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| 177Lu-DOTATOCLutetium Lu 177-Edotreotide | II | 1 | NCT06045260 |
| [18F]FAPI-74 | II | 1 | NCT06503146 |
| AnlotinibAL3818, Anrotinib | II | 1 | NCT06429397 |
| BenmelstobartTQB2450 | II | 1 | NCT06429397 |
| Dotatate | II | 1 | NCT04711135 |
| Ga-68-DOTATATE | II | 1 | NCT03206060 |
| HTL0039732 | I–II | 1 | NCT05944237 |
| Ivocizumab | II | 1 | NCT06683846 |
| IvonescimabAK112 | II | 1 | NCT07743138 |
| Lu-177-DOTATATE | II | 1 | NCT03206060 |
| Tipifarnib | II | 1 | NCT04284774 |
| ZanzalintinibXL092 | II | 1 | NCT07714551 |
| ADCT-701 | I | 1 | NCT06041516 |
| 18F-MFBG | Early I | 1 | NCT05069220 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| 68Ga-DOTATATEGallium 68 Dotatate, Gallium Ga 68-DOTATATE | I–II | 3 | NCT06427798 |
| BelzutifanWelireg® | II | 3 | NCT04924075 |
| LutatheraLutetium Lu 177 Dotatate, 177Lu-DOTATATE | I–II | 2 | NCT06607692 |
| OlaparibAZD2281, Lynparza® | I–II | 2 | NCT06607692 |
| 18F-FDG^1^8F-fluorodeoxyglucose, Fludeoxyglucose F-18 | II | 1 | NCT06503146 |
| AtezolizumabTecentriq, MPDL3280A | I–II | 1 | NCT05944237 |
| AxitinibInlyta®, Axitinib Accord® | II | 1 | NCT03839498 |
| Iobenguane I 131Azedra® | II | 1 | NCT00107289 |
| IpilimumabYERVOY, ipililumab IV | II | 1 | NCT02834013 |
| LanreotideSomatuline Depot® | II | 1 | NCT03946527 |
| NivolumabOpdivo, ONO-4538 | II | 1 | NCT02834013 |
| PembrolizumabKEYTRUDA, MK-3475 | II | 1 | NCT02721732 |
| TemozolomideTemodal, Temodar | II | 1 | NCT04394858 |
| CyclophosphamideCyclophosphamid, Cytoxan | I | 1 | NCT04119024 |
| FludarabineFludara, FLUDARABIN | I | 1 | NCT04119024 |
Sorted by most advanced phase and number of active trials.
All 29 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Neuroectodermal tumor 3 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Nerve tissue neoplasm 4 drugs
- Neoplasm 671 drugs
- Neuroendocrine tumor 84 drugs
- Glandular and epithelial neoplasm 12 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D010673 “Pheochromocytoma”.